These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

336 related articles for article (PubMed ID: 34503964)

  • 1.
    Nienhuis PH; Antunes IF; Glaudemans AWJM; Jalving M; Leung D; Noordzij W; Slart RHJA; de Vries EFJ; Hospers GAP
    J Nucl Med; 2022 Jun; 63(6):899-905. PubMed ID: 34503964
    [TBL] [Abstract][Full Text] [Related]  

  • 2.
    Verhoeff SR; van de Donk PP; Aarntzen EHJG; Oosting SF; Brouwers AH; Miedema IHC; Voortman J; Menke-van der Houven van Oordt WC; Boellaard R; Vriens D; Slingerland M; Hermsen R; Grunsven IVE; Heskamp S; van Herpen CML
    J Nucl Med; 2022 Oct; 63(10):1523-1530. PubMed ID: 35512998
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Interleukin-2 PET imaging in patients with metastatic melanoma before and during immune checkpoint inhibitor therapy.
    van de Donk PP; Wind TT; Hooiveld-Noeken JS; van der Veen EL; Glaudemans AWJM; Diepstra A; Jalving M; de Vries EGE; de Vries EFJ; Hospers GAP
    Eur J Nucl Med Mol Imaging; 2021 Dec; 48(13):4369-4376. PubMed ID: 34076745
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cancer immunotherapy is accompanied by distinct metabolic patterns in primary and secondary lymphoid organs observed by non-invasive
    Schwenck J; Schörg B; Fiz F; Sonanini D; Forschner A; Eigentler T; Weide B; Martella M; Gonzalez-Menendez I; Campi C; Sambuceti G; Seith F; Quintanilla-Martinez L; Garbe C; Pfannenberg C; Röcken M; la Fougere C; Pichler BJ; Kneilling M
    Theranostics; 2020; 10(2):925-937. PubMed ID: 31903160
    [No Abstract]   [Full Text] [Related]  

  • 5. More advantages in detecting bone and soft tissue metastases from prostate cancer using
    Pianou NK; Stavrou PZ; Vlontzou E; Rondogianni P; Exarhos DN; Datseris IE
    Hell J Nucl Med; 2019; 22(1):6-9. PubMed ID: 30843003
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Quantitative imaging biomarkers of immune-related adverse events in immune-checkpoint blockade-treated metastatic melanoma patients: a pilot study.
    Hribernik N; Huff DT; Studen A; Zevnik K; Klaneček Ž; Emamekhoo H; Škalic K; Jeraj R; Reberšek M
    Eur J Nucl Med Mol Imaging; 2022 May; 49(6):1857-1869. PubMed ID: 34958422
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Exploring the predictive potential of programmed death ligand 1 expression in healthy organs and lymph nodes as measured by
    Miedema IHC; Pouw JEE; Kwakman A; Zwezerijnen GJC; Huisman MC; Timmer FEF; van de Ven R; de Gruijl TD; Hospers GAP; de Langen AJ; Menke-van der Houven van Oordt CW
    J Immunother Cancer; 2024 Jun; 12(6):. PubMed ID: 38886117
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The Value of
    Vekens K; Everaert H; Neyns B; Ilsen B; Decoster L
    Clin Lung Cancer; 2021 Sep; 22(5):432-440. PubMed ID: 33879398
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparison of 18F-FDG PET/CT Criteria for the Prediction of Therapy Response and Clinical Outcome in Patients With Metastatic Melanoma Treated With Ipilimumab and PD-1 Inhibitors.
    Annovazzi A; Vari S; Giannarelli D; Pasqualoni R; Sciuto R; Carpano S; Cognetti F; Ferraresi V
    Clin Nucl Med; 2020 Mar; 45(3):187-194. PubMed ID: 31977479
    [TBL] [Abstract][Full Text] [Related]  

  • 10.
    Ito K; Teng R; Schöder H; Humm JL; Ni A; Michaud L; Nakajima R; Yamashita R; Wolchok JD; Weber WA
    J Nucl Med; 2019 Mar; 60(3):335-341. PubMed ID: 30413661
    [TBL] [Abstract][Full Text] [Related]  

  • 11. PD-L1 PET/CT Imaging with Radiolabeled Durvalumab in Patients with Advanced-Stage Non-Small Cell Lung Cancer.
    Smit J; Borm FJ; Niemeijer AN; Huisman MC; Hoekstra OS; Boellaard R; Oprea-Lager DE; Vugts DJ; van Dongen GAMS; de Wit-van der Veen BJ; Thunnissen E; Smit EF; de Langen AJ
    J Nucl Med; 2022 May; 63(5):686-693. PubMed ID: 34385342
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Role of quantitative imaging biomarkers in an early FDG-PET/CT for detection of immune-related adverse events in melanoma patients: a prospective study.
    Hribernik N; Strasek K; Huff DT; Studen A; Zevnik K; Skalic K; Jeraj R; Rebersek M
    Radiol Oncol; 2024 Sep; 58(3):335-347. PubMed ID: 39287171
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Assessing immune organs on
    Prigent K; Lasnon C; Ezine E; Janson M; Coudrais N; Joly E; Césaire L; Stefan A; Depontville M; Aide N
    Eur J Nucl Med Mol Imaging; 2021 Jul; 48(8):2573-2585. PubMed ID: 33432374
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prognostic 18F-FDG PET biomarkers in metastatic mucosal and cutaneous melanoma treated with immune checkpoint inhibitors targeting PD-1 and CTLA-4.
    Seban RD; Moya-Plana A; Antonios L; Yeh R; Marabelle A; Deutsch E; Schwartz LH; Gómez RGH; Saenger Y; Robert C; Ammari S; Dercle L
    Eur J Nucl Med Mol Imaging; 2020 Sep; 47(10):2301-2312. PubMed ID: 32206839
    [TBL] [Abstract][Full Text] [Related]  

  • 15.
    Wardak M; Sonni I; Fan AP; Minamimoto R; Jamali M; Hatami N; Zaharchuk G; Fischbein N; Nagpal S; Li G; Koglin N; Berndt M; Bullich S; Stephens AW; Dinkelborg LM; Abel T; Manning HC; Rosenberg J; Chin FT; Gambhir SS; Mittra ES
    Radiology; 2022 Jun; 303(3):620-631. PubMed ID: 35191738
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Radiomics, Tumor Volume, and Blood Biomarkers for Early Prediction of Pseudoprogression in Patients with Metastatic Melanoma Treated with Immune Checkpoint Inhibition.
    Basler L; Gabryś HS; Hogan SA; Pavic M; Bogowicz M; Vuong D; Tanadini-Lang S; Förster R; Kudura K; Huellner MW; Dummer R; Guckenberger M; Levesque MP
    Clin Cancer Res; 2020 Aug; 26(16):4414-4425. PubMed ID: 32253232
    [TBL] [Abstract][Full Text] [Related]  

  • 17. (18)F-fluorodeoxyglucose positron emission tomography/computed tomography and magnetic resonance imaging in patients with liver metastases from uveal melanoma: results from a pilot study.
    Orcurto V; Denys A; Voelter V; Schalenbourg A; Schnyder P; Zografos L; Leyvraz S; Delaloye AB; Prior JO
    Melanoma Res; 2012 Feb; 22(1):63-9. PubMed ID: 22027909
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Interim [
    Sachpekidis C; Kopp-Schneider A; Pan L; Papamichail D; Haberkorn U; Hassel JC; Dimitrakopoulou-Strauss A
    Eur J Nucl Med Mol Imaging; 2021 Jun; 48(6):1932-1943. PubMed ID: 33336264
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Is there a link between very early changes of primary and secondary lymphoid organs in
    Seith F; Forschner A; Weide B; Gückel B; Schwartz M; Schwenck J; Othman AE; Fenchel M; Garbe C; Nikolaou K; Schwenzer N; la Fougère C; Pfannenberg C
    J Immunother Cancer; 2020 Aug; 8(2):. PubMed ID: 32753543
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Quantification of PD-L1 Expression with
    Huisman MC; Niemeijer AN; Windhorst AD; Schuit RC; Leung D; Hayes W; Poot A; Bahce I; Radonic T; Oprea-Lager DE; Hoekstra OS; Thunnissen E; Hendrikse NH; Smit EF; de Langen AJ; Boellaard R
    J Nucl Med; 2020 Oct; 61(10):1455-1460. PubMed ID: 32060213
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.